Xencor (NASDAQ:XNCR) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Xencor (NASDAQ:XNCRGet Rating) in a research note published on Wednesday, The Fly reports. The firm issued an overweight rating and a $37.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on XNCR. Canaccord Genuity Group reiterated a buy rating and issued a $50.00 price objective on shares of Xencor in a report on Wednesday, July 6th. StockNews.com downgraded Xencor from a hold rating to a sell rating in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $49.71.

Xencor Trading Down 2.4 %

NASDAQ XNCR opened at $26.95 on Wednesday. The stock has a 50-day simple moving average of $28.64 and a 200 day simple moving average of $26.90. The company has a market capitalization of $1.61 billion, a PE ratio of 79.27 and a beta of 0.62. Xencor has a 12 month low of $19.35 and a 12 month high of $43.61.

Xencor (NASDAQ:XNCRGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). The company had revenue of $30.18 million during the quarter, compared to the consensus estimate of $34.35 million. Xencor had a net margin of 7.77% and a return on equity of 3.15%. As a group, sell-side analysts predict that Xencor will post -1.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

Several large investors have recently modified their holdings of the business. US Bancorp DE boosted its position in shares of Xencor by 324.9% during the second quarter. US Bancorp DE now owns 939 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 718 shares during the period. Nisa Investment Advisors LLC acquired a new position in shares of Xencor during the second quarter worth about $27,000. Prospera Financial Services Inc acquired a new position in shares of Xencor during the first quarter worth about $28,000. Point72 Hong Kong Ltd acquired a new position in shares of Xencor during the fourth quarter worth about $41,000. Finally, Lazard Asset Management LLC boosted its position in shares of Xencor by 203.0% during the first quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 3,005 shares during the period. 99.28% of the stock is currently owned by institutional investors.

Xencor Company Profile

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Read More

The Fly logo

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.